GLYCOTOPE Moves PankoMab(TM) Towards Phase-II Clinical Development
GLYCOTOPE is due to successfully complete Phase I of its glycooptimized therapeutic antibody PankoMab(TM) and will move…
GLYCOTOPE is due to successfully complete Phase I of its glycooptimized therapeutic antibody PankoMab(TM) and will move…
After successful completion of Phase I, the German biotech company GLYCOTOPE moves its glycooptimized therapeutic protei…
Die Berliner Glycotope GmbH, das international führende Unternehmen der Glykobiologie, ist der Preisträger in der Sparte…
Glycotope GmbH, a leading glycobiology company, will present recent advances with its GlycoExpress(TM) technology of nov…
Glycotope GmbH, a leading glycobiology company, has received regulatory approval by German and Italian regulatory author…
Glycotope GmbH, a leading German Biotech company, has received regulatory approval by Germany and Italian regulatory aut…